A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 4

Conditions: Rheumatoid Arthritis

Treatments: Drug: Comparator: naproxen tablet 500 mg; Drug: MK0966; rofecoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00157872

2005_063

0966-231

Details and patient eligibility

About

A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Chinese males or females at least 18 years of age with rheumatoid arthritis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind